The effects of oral trehalose on glycaemia, inflammation, and quality of life in patients with type 2 diabetes: a pilot randomized controlled trial.
| Autor: | Hashemian S; Applied Biomedical Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran., Shojaei M; Nutrition and Food Security Research Centre and Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran., Radbakhsh S; Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.; Department of Medical Biotechnology and Nanotechnology, Mashhad University of Medical Sciences, Mashhad, Iran., Ashari S; Applied Biomedical Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran., Matbou Riahi M; Applied Biomedical Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran., Shateri Amiri Z; Department of Community Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Atkin SL; School of Postgraduate Studies and Research, RCSI Medical University of Bahrain, Busaiteen, Bahrain., Banach M; Department of Preventive Cardiology, Medical University of Lodz (MUL), Lodz, Poland.; Cardiovascualr Research Centre, University of Zielona Gora, Zielona Gora, Poland.; Department of Cardiology and Congenital Diseases of Adults, Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland., Bagherniya M; Nutrition and Food Security Research Centre and Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.; Anesthesia and Critical Care Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran., Emami SA; Department of Traditional Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran., Sahebkar A; Biotechnology Research Centre, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.; Applied Biomedical Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran.; School of Medicine, The University of Western Australia, Perth, Australia.; Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Archives of medical science : AMS [Arch Med Sci] 2023 Jan 05; Vol. 19 (6), pp. 1693-1700. Date of Electronic Publication: 2023 Jan 05 (Print Publication: 2023). |
| DOI: | 10.5114/aoms/159048 |
| Abstrakt: | Introduction: Trehalose is a naturally occurring disaccharide of 2 glucose molecules, which has been suggested as a potential therapeutic agent to reduce blood glucose and ameliorate diabetes-related complications in type 2 diabetes (T2D). This study aimed to determine the efficacy of medium-term trehalose treatment in patients with T2D. Material and Methods: A double-blind, randomized, placebo-controlled trial in 40 patients with T2D was undertaken; 20 ingested trehalose 3.3 g/day and 20 placebo (sucrose), for 3 months. Parameters of glycaemic indices, high-sensitivity C-reactive protein (CRP), mood status, and quality of life were measured. Results: CRP was significantly lower with trehalose treatment (-0.62 ±0.3 mg/l, p = 0.02); however, no differences in glycaemic indices of fasting blood glucose (FBG) (-7.1 ±10.7 mg/dl, p = 0.15), glycated hemoglobin (HbA Conclusions: 12 weeks of treatment with 3.3 g/day of oral trehalose significantly improves CRP as a marker of inflammation, with potential favourable effects on quality of life, depression, and stress levels, but overall glycaemic control and pro-oxidant-antioxidant balance were unaltered during this time frame. Competing Interests: The authors declare no conflict of interest. (Copyright: © 2023 Termedia & Banach.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|